Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Acrivon Therapeutics (Nasdaq: ACRV) approved an inducement equity award under its 2023 Inducement Plan on April 15, 2026. The company granted stock options to one employee to purchase 111,150 shares, with exercise price set at the Nasdaq closing price on the grant date and standard time-based vesting.

Market Context

This announcement detailed a standard inducement option grant of 111,150 shares to a new employee un...

Analysis

This announcement detailed a standard inducement option grant of 111,150 shares to a new employee under Nasdaq Rule 5635(c)(4), struck at the market closing price and vesting 25% after one year with 2.083% monthly thereafter. It follows earlier equity awards to executives and sits against a backdrop of ongoing clinical work and prior filings. Investors may watch how cumulative equity grants interact with ACRV’s cash runway and clinical milestones.

Key Figures

Inducement options: 111,150 shares Initial vesting: 25% Ongoing vesting: 2.083% monthly +1 more

4 metrics

Inducement options 111,150 shares Stock options granted to one employee under 2023 Inducement Plan

Initial vesting 25% Vests on first anniversary of month after employment start

Ongoing vesting 2.083% monthly Additional vesting installments after initial cliff, service-based

Nasdaq Rule 5635(c)(4) Basis for inducement grant approval by Board

Historical Context

5 past events · Latest: Mar 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 19	Earnings & pipeline update	Positive	+3.7%	Reported strong ACR-368 data, cash runway into 2027, and 2025 financials.
Mar 17	Preclinical combo data	Positive	-1.2%	Announced AP3-guided ACR-368 and ACR-2316 synergy data for AACR 2026.
Feb 24	Conference presentation	Neutral	+0.0%	Planned TD Cowen fireside chat with webcast for investors.
Feb 23	KOL panel event	Neutral	-2.0%	Announced KOL panel and ESGO oral presentation on ACR-368 trial data.
Feb 18	CLIA lab launch	Positive	-0.6%	Completed CLIA-certified lab to support companion diagnostics and AP3 programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent ACRV news has often seen muted or mixed price responses, including several positive clinical and corporate updates that did not translate into sustained upside, suggesting a cautious market stance toward the story.

Recent Company History

Over the last few months, ACRV reported Q4 and full-year 2025 results with a 52% cORR in serous endometrial cancer and $118.6M in cash funding operations into Q2 2027. It highlighted AP3-driven combination data at AACR, announced a CLIA-certified internal lab, and scheduled investor-facing events such as a KOL panel and conference presentations. The current inducement option grant fits into this pattern of ongoing operational and governance updates without major strategic shifts.

Key Terms

nasdaq listing rule 5635(c)(4), stock options, exercise price, equity award, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"Announces inducement grant under Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"The equity award was granted in the form of stock options..."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The stock options have an exercise price per share equal to the closing price..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equity award financial

"the company approved a grant of equity award under its 2023 Inducement Plan..."

An equity award is a form of pay where a company gives employees, executives or other stakeholders the right to own or buy company shares—either immediately or after meeting certain conditions. Think of it like receiving slices of the company pie now or coupons to claim slices later; it matters to investors because it affects ownership dilution, executive incentives and reported compensation costs, and signals how management is being rewarded and retained.

inducement grants financial

"The inducement grants were approved by Acrivon’s Board of Directors..."

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of April 15, 2026.

The employee received an aggregate of options to purchase 111,150 shares of Acrivon common stock. The stock options have an exercise price per share equal to the closing price of Acrivon’s common stock on the Nasdaq Global Market on the date of grant. The stock options will vest 25% on the first anniversary of the first day of the month following the effective date of such employee’s employment and in additional 2.083% installments on a monthly basis thereafter, subject to such employee’s continued employment on each vesting date.

The inducement grants were approved by Acrivon’s Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).

About Acrivon Therapeutics
Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.

Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.

In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing, with weekly dosing regimens established. Initial data has shown a favorable tolerability profile limited to transient, mechanism-based hematological adverse events, predominantly neutropenia and initial clinical activity across AP3-selected solid tumor types, including PRs in endometrial cancer, as well as SCLC and sqNSCLC, two tumor types which have not shown sensitivity to other clinical WEE1 or PKMYT1 inhibitors currently in development. In addition, the company is advancing ACR-6840, an internally discovered development candidate targeting CDK11.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.

Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com

Alexandra Santos
asantos@wheelhouselsa.com

FAQ

What did Acrivon (ACRV) announce on April 15, 2026 about an inducement grant?

Acrivon granted stock options to one employee to purchase 111,150 shares as an inducement to employment. According to the company, the grant date was April 15, 2026 and the exercise price equals the Nasdaq closing price on that date.

How do the Acrivon (ACRV) inducement stock options vest and when does vesting begin?

The options vest 25% after one year, then 2.083% monthly thereafter, subject to continued employment. According to the company, vesting begins after the first anniversary of the first day of the month following employment start.

What exercise price applies to Acrivon (ACRV) inducement options granted April 15, 2026?

The exercise price equals Acrivon's closing price on Nasdaq on the grant date, April 15, 2026. According to the company, the per-share exercise price is set to the Nasdaq closing price on that specific date.

Why did Acrivon (ACRV) issue the option grant under Nasdaq Rule 5635(c)(4)?

The Board approved the grant as a material inducement to employment in compliance with Nasdaq Rule 5635(c)(4). According to the company, the approval satisfied Nasdaq requirements for inducement equity awards.

How many shares were covered by the April 15, 2026 Acrivon (ACRV) inducement grant?

The inducement award covers 111,150 options to purchase shares of Acrivon common stock. According to the company, the aggregate number of options granted to the employee was 111,150 on the grant date.